Aurinia Pharmaceuticals Inc Stock News

Aurinia Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing therapies for diseases with high unmet medical need. The company has been the subject of frequent takeo

Aurinia Pharmaceuticals, an autoimmune disease specialist, is trading lower on high volume today. The biotech's shares have been trading at a premium all year long.

Innovation is expected to continue driving growth in the Medical-Drugs industry. CORT, AUPH, ALPN, KALV and CRDL may prove to be good additions to one's portfolio.

Here is how Aurinia Pharmaceuticals (AUPH) and Bausch Health (BHC) have performed compared to their sector so far this year.

Aurinia Pharmaceuticals (AUPH) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.20. This compares to loss of $0.25 per share a year ago.

EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals to Release Second Quarter Financial and Operational Results on August 3, 2023.

Aurinia (AUPH) surges as management decides to explore strategic business options, including potential sale or a merger.

Aurinia (AUPH) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Thursday, Aurinia's board of directors announced plans to explore strategic alternatives to bolster shareholder value. Investors are piling into the biotech's shares today as a result.

In the most recent earnings period of Q1 of 2023, Aurinia Pharmaceuticals Inc. reported 59% year-over-year growth in revenue of LUPKYNIS™ to $34.4 million. Full-year 2023 revenue guidance range was

Two of Aurinia's largest shareholders wrote tough letters against the AUPH board, leading to two resignations. One of these shareholders also wanted AUPH to sell out.

Does Aurinia Pharmaceuticals (AUPH) have what it takes to be a top stock pick for momentum investors? Let's find out.

Start Time: 08:30 January 1, 0000 9:27 AM ET Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH ) Q1 2023 Earnings Conference Call May 04, 2023, 08:30 AM ET Company Participants Peter Greenleaf - President and

Aurinia Pharmaceuticals (AUPH) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.24. This compares to loss of $0.27 per share a year ago.

With multiple blockbuster drugs going off patent this decade, pharma companies are expected to ratchet up their M&A activities. These three companies sport high-value assets that could attract suitors